Introduction
============

Ovarian cancer (OC) is one of the most common malignancies in women, which accounts for 2.5% of cancers in women [@B1]-[@B2]. Approximately 13,850 women died from OC annually, being one of the leading reasons for cancer deaths in women in the United States and the 5-year survival rate for women with all types of ovarian cancer was around 47% [@B3]-[@B5]. More than 60% OC patients were diagnosed at an advanced stage, with de novo distant metastases, which can partly explain the high mortality rate [@B6].

In the latest study, bone was reported to be the fourth common metastatic sites followed by liver, distant lymph nodes and lung [@B7]. Advanced bone metastases (BM) commonly result in skeletal related events (SREs), including pathological fracture, pain, bone marrow aplasia, spinal cord compression, and malignant hypercalcemia, which significantly worsen the quality of life [@B8], [@B9].

There are no current routine BM screening guidelines for OC patients. Survival rates are lower than other cancers as OC lacks specific early symptoms, which delays diagnosis and treatment [@B10]. In order to improve BM identification and provide early screening for BM, the study focused on the risk factors of BM occurrence in OC.

Early estimation of the prognosis for metastatic OC can help the physicians to develop targeted treatment regimens. Prophylactic treatment and attentive nursing care can be given to the patients with high risk to improve the prognosis. However, limited studies on the survival estimates of bone metastatic OC patients were performed before.

National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER), as the largest publicly available cancer dataset, covers approximately 30% of the US population and routinely records patients\' demographics, tumor characteristics, general treatment, survival time, and annually updated vital status. The primary aim of the present study was to investigate the prevalence and the risk factors of de novo BM in OC in the SEER dataset. The secondary aim was to explore the over survival and prognostic factors of OC with de novo BM.

Methods
=======

Study population
----------------

Adult OC patients were identified using the SEER database. Primary OC patients initially diagnosed between 2010 and 2015 were collected (the details of BM were not recorded before 2010, and the latest data up to date is to December 31, 2015). The site recodes ICD-O-3 (International Classification of Diseases for Oncology-3)/WHO 2008 was restricted as "Ovarian". The exclusion criteria were as follows: patients younger than 18 years old; diagnosed with carcinoma in situ, benign or borderline tumors, diagnosed at autopsy or via death certificate, unknown information for BM or follow-up. SEER\*Stat 8.3.5 software (<https://seer.cancer.gov/data/>) was used to generate the case listing.

Study design
------------

It was a population-based cohort study. The prevalence and associated factors for BM were described using OC patients diagnosed from January 1, 2010, to December 31, 2015. The OC patients with BM were followed up to conduct survival analysis and investigate the prognostic factors.

Statistical analysis
--------------------

Patients\' demographic and clinical characteristics were defined as follows: age (18-40, 41-64 and ≥65 years), race (white, black and others), marital status (married and unmarried), insurance status (insured and uninsured), laterality (left, right and bilateral), primary tumor stage (T stage: T1, T2 and T3), regional lymph node stage (N stage: N0 and N1), tumor grade (I=well differentiated, II=moderately differentiated, III=poorly differentiated and Ⅳ=undifferentiated and anaplastic), histology (serous and non-serous), cancer antigen 125 (CA-125: normal and elevated), and the presence of lung metastases, liver metastases, and brain metastases. Quantitative data were described as mean ± standard deviation (SD) and the difference between groups were analysed by student\'s t-test. Categorical data were presented as number and the percentage (N, %) and the differences were tested by Pearson chi-square test. The risk factors for OC patients with initial BM were determined primarily by univariable logistic regression. The characteristics with *P*\<0.05 in the univariable logistic regression analysis were considered as candidates for the multivariable logistic analysis. The overall survival was estimated by Kaplan-Meier method and the difference between distinct groups was compared using the log-rank test. Multivariable Cox regression model, incorporating the significant factors in univariate Cox regression (*P\<*0.05) was conducted for analyzing the independent prognostic factors for BM.

All statistical analyses were performed using SPSS 23.0 (IBM Corporation, Armonk, NY) and all survival curves were conducted by MedCalc 15.2.2. A two-tailed *P* value *\<*0.05 was considered statistically significant in all analyses.

Results
=======

Demographic and clinical characteristics
----------------------------------------

A total of 32,178 OC patients met the inclusion criteria (Figure [1](#F1){ref-type="fig"}). The patients\' mean age was 61.82 ±14.97 years. Among these patients, 352 OC patients with BM were retrieved, and the mean age of them was 65.61±15.12 years. The demographic and clinical characteristics of the included patients were shown in Table [1](#T1){ref-type="table"}.

Prevalence of BM
----------------

352 OC patients were diagnosed with de novo BM (1.09%). There is significant difference in the BM prevalence across different age groups (*χ*^2^=16.29, *P*\<0.001), and the prevalence in the advanced ages groups (≥65 years) was higher than that in 18-40 years (*χ*^2^=4.92, *P*=0.027) and 41-64 years (*χ*^2^=14.21, *P*=0.0002). Results also showed the BM prevalence in black (compared with white patients; *χ*^2^=8.88, *P*=0.01), unmarried status (*χ*^2^=7.97, *P*=0.01), T2 stage (*χ*^2^=35.59, *P*\<0.001), N1 stage (*χ*^2^=74.84, *P*\<0.001), poor differentiated grade (*χ*^2^=20.69, *P*\<0.001), non-serous (*χ*^2^=70.89, *P*\<0.001), elevated CA-125 (*χ*^2^=6.02, *P*=0.01), lung metastases (*χ*^2^=642.95, *P*\<0.001), liver metastases (*χ*^2^=606.90, *P*\<0.001) and brain metastases (*χ*^2^=460.19, *P*\<0.001) were all significantly higher than in the other groups (Table [1](#T1){ref-type="table"}).

Associated factors for developing BM
------------------------------------

Univariable logistic analysis showed the factors of advanced age, unmarried status, higher T stage, N1 stage, poor differentiated grade, non-serous histology, elevated CA-125, the presence of lung metastases, liver metastases, and brain metastases were all positively associated with BM risk (Table [2](#T2){ref-type="table"}).

Multivariable logistic regression indicated advanced age was negatively associated with BM, while the T2/T1 stage, N1/N0 stage, non-serous and the presence of lung and liver metastases were positively associated with de novo BM development (Table [2](#T2){ref-type="table"}).

Survival analysis and prognostic factors for BM
-----------------------------------------------

Once patients developed BM, OC patients\' survival was dramatically decreased. The median survival of the cohort was 50.00 months (95% CI: 48.44-51.56 months), while for the 352 OC patients with de novo BM, median survival was 5.00 months (95% CI: 3.76-6.24 months, Figure [2](#F2){ref-type="fig"} A). Kaplan-Meier analysis showed the overall survival in subjects with advanced age (Figure [2](#F2){ref-type="fig"} B,*P*=0.01), unmarried status (Figure [2](#F2){ref-type="fig"} C, *P*=0.004), non-serous (Figure [2](#F2){ref-type="fig"} D, *P*\<0.001) and with lung metastases (Figure [2](#F2){ref-type="fig"} E,*P*=0.02) and liver metastases (Figure [2](#F2){ref-type="fig"} F,*P*=0.001) were shorter than their counterparts. Patients with surgical treatment of the primary site presented significantly higher overall survival rate than those without surgery (Figure [2](#F2){ref-type="fig"} G*, P*\<0.001).

Multivariable Cox regression results incorporating the aforementioned significant factors showed that non-serous histology \[Hazard ratio (HR)=3.05; 95% CI: 1.63-5.72; *P*=0.001\] was positively associated with overall death, while the surgery of the primary site (HR=0.42; 95% CI: 0.29-0.61; *P*\<0.001) were showed to be negatively associated with overall death risk. Moreover, the median survival time could be prolonged from 3.00 (95% CI: 2.20-3.80) months to 18.00 (95% CI: 10.82-25.18) months in patients with history of primary site surgery (Table [3](#T3){ref-type="table"}).

Discussion
==========

One of the greatest strengths of the present study was the large sample size provided by SEER database. With the large population, the present study was the first time looking into both risk factors for BM occurrence and prognostic factors of OC patients with BM. Based on our cohort analyses, 1.09% of the OC patients were diagnosed with de novo BM, which was consistent with previous studies. It was previously reported that the incidence of BM ranged from 1.5% to 3.74% among OC patients [@B1], [@B11]. However, the prevalence of BM in OC was 15% in autopsy studies, because approximately 50% of the metastatic sites were asymptomatic [@B12].

According to our extensive literature review, this is the first time to investigate the associated factors for BM in OC patients. A previous study suggested advanced stage, poor differentiated grade, and lymph node involvement were positively associated with development of distant metastases [@B7]. The present study added to the literature by showing older age, T2/T1 stage, N1/N0 stage, non-serous and the presence of lung and liver metastases were all significantly associated with de novo BM development. Risk factors identification is important for guiding clinical treatment procedures. The prophylactic treatment and nursing can be given to the OC patients with more risk factors. Screening examinations such as skeletal radiographic scanning and/or PET-CT can be recommended for the patients with high BM risk. A predictive system can be fabricated to quantitively evaluate the probability of the BM development in the future.

The association between histological types and BM development in OC is still controversial. A series of studies reported that the histological types did not affect the development of BM [@B13]-[@B15]. Based on previous autopsy studies with the limited sample size, Abdul-Karim and colleagues reported that BM tends to occur in high-grade carcinomas instead of low-grade cases, and was observed in three cases with papillary serous adenocarcinomas, two mixed adenosquamous carcinomas and one clear cell carcinoma [@B16]. Julian *et al.* reported three OC patients with BM, two of them were papillary serous carcinoma and one was with mucinous carcinoma [@B17]. In the present study with a large sample, we proved that BM has a significant higher probability developed in non-serous OC.

Previous studies showed BM could significantly worsen the prognosis of cancer patients [@B18]-[@B21]. The median survival of OC patients with BM were reported to be approximately 8 months [@B7], [@B22], [@B23]. In the present study, the median survival of the entire cohort was 50.00 months, while that of OC patients with de novo BM decreased to 5.00 months. A surprising finding of the present study was the fact that the median survival time can be prolonged from 3.00 months to 18.00 months with primary tumour surgery. Thus, aggressive surgery is encouraged for OC patients with BM. At the same time, non-serous histology showed the negative association with the overall survival. Physicians should pay high attention to the OC patients with the non-serous histological type.

The present study showed the number of BM patients with lung, liver or brain metastasis was lower than those without. BM patients with the present of lung, liver or brain metastasis worsen the prognosis.

It is acknowledged that this study has several limitations. First, the observed BM incidence has to be interpreted as a strong underestimate of the real figure, this is due to the patients who developed BM later in their disease course were not recorded by SEER dataset. Second, the SEER dataset lacks patient comorbidity profiles such as disease history, skeletal related events (SREs) and the patients\' preference to receive surgery, which may partly affect the precision of the results for the prognostic analyses. We found correlation between primary tumor surgery and improved survival among ovarian cancer patients with bone metastases. Due to the insufficient information recorded by SEER on history of diseases and treatment morbidity, external validation is warranted in future. Third, it was not recommended to perform the survival analysis on the SEER cohort as the records of radiotherapy and chemotherapy were lacking [@B24]. Thus, therapeutic related prognostic analyses were not conducted. Last but not least, the diagnostic modes for ovarian cancer patients with bone metastases cannot be analyzed for data undocumented in the SEER database.

Conclusions
===========

The cohort in our study represents the largest dataset of BM in OC to date and offers valuable information on the epidemiological characteristics and prognosis for BM in the OC patient population. The present study provides a uniquely detailed description of associated factors for BM to improve our understanding of BM in OC and potentially guide its clinical procedures.

Bone manifestation is rare in OC patients. A list of risk factors for de novo BM development in OC were identified, including older age, T2/T1 stage, N1/N0 stage, non-serous and the presence of lung and liver metastases. The prognosis of OC patients with de novo BM is poor, with the median survival being 5.00 months. Non-serous histology was positively associated with overall death. Primary tumor surgery was negatively associated with the overall death risk in the present study, more studies with detailed treatment information are needed to further confirm the results.
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###### 

Demographic and clinical characteristics for ovarian cancer patients diagnosed with and without bone metastasis.

  Subject characteristics   No. of ovarian cancer patients (2010-2015)   *χ*^2^         *P*-value   
  ------------------------- -------------------------------------------- -------------- ----------- ---------
  **Age, in years**                                                                     16.29       \<0.001
  18-40                     20(0.82)                                     2413(99.18)                
  41-64                     151(0.91)                                    16417(99.09)               
  ≥65                       181(1.37)                                    12996(98.63)               
  **Race**                                                                              8.88        0.01
  White                     283(1.08)                                    25963(98.92)               
  Black                     45(1.60)                                     2767(98.40)                
  Others                    24(0.81)                                     2939(99.19)                
  Unknown                   0(0.00)                                      157(100.00)                
  **Marital status**                                                                    7.97        0.01
  Married                   145(0.94)                                    15359(99.06)               
  Unmarried                 193(1.27)                                    14982(98.73)               
  Unknown                   14(0.93)                                     1485(99.07)                
  **Insurance**                                                                         0.36        0.55
  Insured                   326(1.07)                                    30140(98.93)               
  Uninsured                 15(1.25)                                     1182(98.75)                
  Unknown                   11(2.14)                                     504(97.86)                 
  **Laterality**                                                                        5.01        0.08
  Left                      52(0.63)                                     8236(99.37)                
  Right                     75(0.87)                                     8579(99.13)                
  Bilateral                 63(0.62)                                     10093(99.38)               
  Unknown                   162(3.19)                                    4918(96.81)                
  **T stage**                                                                           35.59       \<0.001
  T1                        23(0.26)                                     8727(99.74)                
  T2                        46(1.07)                                     4253(98.93)                
  T3                        129(0.80)                                    16097(99.20)               
  Unknown                   154(5.30)                                    2749(94.70)                
  **N stage**                                                                           74.84       \<0.001
  N0                        134(0.59)                                    22550(99.41)               
  N1                        111(1.70)                                    6426(98.30)                
  Unknown                   107(3.62)                                    2850(96.38)                
  **Grade**                                                                             20.69       \<0.001
  Ⅰ                         4(0.17)                                      2336(99.83)                
  Ⅱ                         7(0.21)                                      3331(99.79)                
  Ⅲ                         66(0.76)                                     8618(99.24)                
  Ⅳ                         34(0.54)                                     6314(99.46)                
  Unknown                   241(2.10)                                    11227(97.90)               
  **Histology**                                                                         41.37       \<0.001
  Serous                    87(0.58)                                     14815(99.42)               
  Non-serous                205(1.30)                                    15609(98.70)               
  Unknown                   60(4.10)                                     1402(95.90)                
  **CA-125**                                                                            6.02        0.01
  Normal                    15(0.52)                                     2853(99.48)                
  Elevated                  215(0.99)                                    21441(99.01)               
  Unknown                   122(1.59)                                    7532(98.41)                
  **Lung Met**                                                                          642.95      \<0.001
  None                      207(0.69)                                    29879(99.31)               
  Yes                       127(6.87)                                    1722(93.13)                
  Unknown                   18(7.41)                                     225(92.59)                 
  **Liver Met**                                                                         606.90      \<0.001
  None                      200(0.67)                                    29636(99.33)               
  Yes                       136(6.24)                                    2043(93.76)                
  Unknown                   16(9.82)                                     147(90.18)                 
  **Brain Met**                                                                         460.19      \<0.001
  None                      301(0.94)                                    31705(99.06)               
  Yes                       20(24.69)                                    61(75.31)                  
  Unknown                   31(34.07)                                    60(65.93)                  
  **Sur(pri)**                                                                          526.89      \<0.001
  None                      250(3.63)                                    6645(96.37)                
  Yes                       99(0.39)                                     25132(99.61)               
  Unknown                   3(5.77)                                      49(94.23)                  

**Abbreviations**: BM=bone metastases; CA-125 = cancer antigen 125; Met=metastases; Sur(pri)=surgical treatments on primary site.

###### 

Univariable and Multivariable Logistic Regression for analyzing the associated factors for developing bone metastases in ovarian cancer patients.

  Subject characteristics    Univariable                    Multivariable                      
  -------------------------- -------------------- --------- --------------- ------------------ ---------
  **Age, in years**                                                                            
  18-40                      Reference            1.00                      Reference          1.00
  41-64                      1.11(0.70-1.77)      0.66                      0.40(0.16-1.01)    0.05
  ≥65                        1.68(1.06-2.67)      0.03                      0.35(0.13-0.95)    0.04
  **Marital status**                                                                           
  Married                    Reference            1.00                      Reference          1.00
  Unmarried                  1.37(1.10-1.69)      0.01                      0.92(0.51-1.65)    0.77
  Unknown                    NA                   NA                        NA                 NA
  **T stage**                                                                                  
  T1                         Reference            1.00                      Reference          1.00
  T2                         4.10(2.49-6.78)      \<0.001                   3.39(1.11-10.33)   0.03
  T3                         3.04(1.95-4.74)      \<0.001                   1.78(0.59-5.39)    0.31
  Unknown                    NA                   NA                        NA                 NA
  **N stage**                                                                                  
  N0                         Reference            1.00                      Reference          1.00
  N1                         2.91(2.26-3.74)      \<0.001                   3.17(1.72-5.84)    \<0.001
  Unknown                    NA                   NA                        NA                 NA
  **Differentiated Grade**                                                                     
  Ⅰ                          Reference            1.00                      Reference          1.00
  Ⅱ                          1.23(0.36-4.20)      0.74                      2.04(0.22-18.71)   0.53
  Ⅲ                          4.47(1.63-12.28)     0.004                     4.62(0.60-35.80)   0.14
  Ⅳ                          3.15(1.12-8.87)      0.03                      3.40(0.42-27.48)   0.25
  Unknown                    NA                   NA                        NA                 NA
  **Histology**                                                                                
  Serous                     Reference            1.00                      Reference          1.00
  Non-serous                 2.24(1.74-2.88)      \<0.001                   3.05(1.63-5.72)    0.001
  Unknown                    NA                   NA                        NA                 NA
  **CA-125**                                                                                   
  Normal                     Reference            1.00                      Reference          1.00
  Elevated                   1.91(1.13-3.22)      0.02                      1.33(0.49-3.58)    0.58
  Unknown                    NA                   NA                        NA                 NA
  **Lung Met**                                                                                 
  None                       Reference            1.00                      Reference          1.00
  Yes                        10.65(8.49-13.35)    \<0.001                   8.57(4.37-16.80)   \<0.001
  Unknown                    NA                   NA                        NA                 NA
  **Liver Met**                                                                                
  None                       Reference            1.00                      Reference          1.00
  Yes                        9.86(7.90-12.32)     \<0.001                   4.95(2.50-9.82)    \<0.001
  Unknown                    NA                   NA                        NA                 NA
  **Brain Met**                                                                                
  None                       Reference            1.00                      Reference          1.00
  Yes                        34.54(20.58-57.95)   \<0.001                   5.37(0.37-77.85)   0.22
  Unknown                    NA                   NA                        NA                 NA

**Abbreviations**: CA-125= cancer antigen 125; Met=Metastases; NA=Not available, all factors with Unknown data were removed in logistic regression model.

###### 

Multivariable Cox Regression for analyzing the prognosis factors for ovarian cancer with bone metastases.

  Subject characteristics   Survival, Median (IQR), month   HR (95% CI)       *P*-value
  ------------------------- ------------------------------- ----------------- -----------
  Age, years                                                                  
  18-40                     4.00(2.91-5.09)                 Reference         1.00
  41-64                     7.00(5.14-8.85)                 0.73(0.42-1.26)   0.26
  ≥65                       3.00(2.05-3.95)                 0.73(0.42-1.25)   0.25
  Marital status                                                              
  Married                   7.00(4.73-9.27)                 Reference         1.00
  Unmarried                 3.00(2.03-3.97)                 1.11(0.82-1.49)   0.49
  Unknown                   NA                              NA                NA
  Histology                                                                   
  Serous                    18.00(9.13-26.87)               Reference         1.00
  Non-serous                3.00(1.93-4.08)                 1.44(1.01-2.06)   0.046
  Unknown                   NA                              NA                NA
  Lung Met                                                                    
  None                      6.00(4.04-7.96)                 Reference         1.00
  Yes                       3.00(1.48-4.52)                 1.15(0.84-1.58)   0.37
  Unknown                   NA                              NA                NA
  Liver Met                                                                   
  None                      6.00(4.28-7.72)                 Reference         1.00
  Yes                       3.00(1.52-4.49)                 1.20(0.88-1.64)   0.25
  Unknown                   NA                              NA                NA
  Sur(pri)                                                                    
  None                      3.00(2.20-3.80)                 Reference         1.00
  Yes                       18.00(10.82-25.18)              0.42(0.29-0.61)   \<0.001
  Unknown                   NA                              NA                NA

**Abbreviations**: Met=metastases; Sur(pri)=surgical treatments of primary site, NA=Not available, all factors with Unknown data were removed from Cox and Kaplan-Meier model.
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